Misonidazole Clinical Trials in the United States Radiation Therapy Oncology Group (RTOG)

  • Todd H. Wasserman
  • JoAnn Stetz
  • Theodore L. Phillips
Part of the NATO Advanced Study Institutes Series book series (NSSA, volume 43)


This paper presents a review of the progressive clinical trials of the hypoxic cell radiosensitizer, misonidazole, in the United States. Presentation is made of all the schemas of the recently completed and currently active Radiation Therapy Oncology Group (RTOG) Phase II and Phase III studies. Detailed information is presented on the clinical toxicity of the Phase II trials, specifically regarding neurotoxicity. With limitations in drug total dose, a variety of dose schedules have proven to be tolerable, with a moderate incidence of nausea and vomiting and mild peripheral neuropathy, and a low incidence of more severe peripheral neuropathy or central neuropathy. No other organ toxicity has been seen, specifically no liver, renal or bone marrow toxicities. The clinical pharmacologic monitoring of misonidazole blood levels has been satisfactory with good correlation between the group-wide (Phase II) UV values and the HPLC values from the Phase I study. The patient accrual of the trials has been rapidly increasing and an early analysis suggests efficacy which is better when compared to previous radiation experience. A series of eight Phase III trials are currently underway or proposed in the RTOG and the results of these are pending. An additional Phase III malignant glioma trial in the Brain Tumor Study Group is described.


Peripheral Neuropathy Malignant Glioma Dose Schedule Radiation Therapy Oncology Group Hypoxic Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Committee on Radiation Oncology Studies Research Plan: Radiation Sensitizers, Cancer 37:2062 (1976).Google Scholar
  2. 2.
    T.L. Phillips, T.H. Wasserman, R.J. Johnson, C.J. Gomer, G.A. Lawrence, M.L. Levine, W. Sadee, J.S. Penta and D.J. Rubin, The Hypoxic cell sensitizer programme in the United States, Br. J. Cancer 37: Suppl.III, 276 (1978).Google Scholar
  3. 3.
    P. Rubin, R.B. Cowan and D.J. Rubin, The radiation oncology research program, B. Radiosensitizers/radioprotectors working group, Int.J.Radiation Oncology Biol.Phys. 5:651(1979).CrossRefGoogle Scholar
  4. 4.
    J.D. Chapman, Current concepts in cancer: Hypoxic sensitizers-implications for radiation therapy, New.Eng.J.Med. 301:1429 (1979).PubMedCrossRefGoogle Scholar
  5. 5.
    T.H. Wasserman, T.L. Phillips, R.J. Johnson, C.J. Gomer, G.A. Lawrence, W. Sadee, R.A. Marques, V.A. Levin and G. VanRaalte, Initial United States clinical and pharmacologic evaluation of misonidazole (RO-07–0582) an hypoxic cell radio sensitizer, Int.J.Radiation Oncology Biol. Phys. 5:775 (1979).CrossRefGoogle Scholar
  6. 6.
    T.L. Phillips, T.H. Wasserman, R.J. Johnson, V.A. Levin and G. VanRaalte, Final report on the United States Phase I clinical trial of the hypoxic cell radiosensitizer, Misonidazole, Cancer, In press (1980).Google Scholar
  7. 7.
    T.H. Wasserman, T.L. Phillips, G.V. VanRaalte, R.C. Urtasun, J. Partington, A. Kozio, J.G. Schwade, D. Ganji and J.M. Strong, The neurotoxicity of misonidazole: Potential modifying role of phenytoin sodium and dexamethasone, Br. J. Radiol. 53:172 (1980).PubMedCrossRefGoogle Scholar
  8. 8.
    S.C. Carabell, L.A. Bruno, A.S. Weinstein, M.P. Richter, C.B. Weiler and R.L. Goodman, Misonidazole and radiotherapy in the treatment of malignant glioma: A Phase II trial, Int.J.Radiation Oncology Biol.Phys. 5:Suppl.2, 194 (1979).CrossRefGoogle Scholar
  9. 9.
    S.C. Carabell, L.A. Bruno, A.S. Weinstein, M.P. Richter, C.H. Chang, C.B. Weiler and R.L. Goodman, Misonidazole and Radiotherapy in the treatment of malignant glioma: A Phase II trial of the Radiation Therapy Oncology Group, Int.J.Radiation Oncology Biol.Phys. In Press (1980).Google Scholar
  10. 10.
    J.T. Fazekas, The value of adjuvant misonidazole in the definitive irradiation of advanced head and neck squamous cancer: An RTOG pilot study (#78–02), Int.J.Radiation Oncology Biol.Phys. 5:Suppl.2, 186, (1979).CrossRefGoogle Scholar
  11. 11.
    T.L. Phillips, J. Newall, S.E. Order, P. Rubin, W.M. Wara and T.H. Wasserman, A Phase II Evaluation of misonidazole in patients with brain metastases. Abstract ASTR. (1980).Google Scholar
  12. 12.
    S. Leibel et al. Abstract ASTR. (1980).Google Scholar
  13. 13.
    J.R. Simpson, C.A. Perez, T.L. Phillips, J.P. Concannon, R.J. Carella, Large fraction radiotherapy plus misonidazole in the treatment of advanced lung cancer: Report of Phase I/II trial. Abstract ASTR. (1980).Google Scholar
  14. 14.
    T.H. Wasserman, T.L. Phillips and G. VanRaalte, Evaluation of the bioavailability of misonidazole in capsule, and tablet form, Abstract, ASTR, Int.J.Radiation Oncology Biol.Phys. In press, (1980).Google Scholar
  15. 15.
    M.D. Walker and T.A. Strike, A phase II evaluation of misonidazole in the treatment of malignant glioma, Abstract, Proc. Amer.Soc.Clinical Oncology 20:433 (1979).Google Scholar

Copyright information

© Plenum Press, New York 1982

Authors and Affiliations

  • Todd H. Wasserman
    • 1
  • JoAnn Stetz
    • 2
  • Theodore L. Phillips
    • 3
  1. 1.Division of Radiation Oncology, Mallinckrodt Institute of RadiologyWashington University School of MedicineUSA
  2. 2.Radiation Therapy Oncology GroupPhiladelphiaUSA
  3. 3.Department of Radiation OncologyUniversity of California at San FranciscoSan FranciscoUSA

Personalised recommendations